E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- to assess the effect of telaprevir on genotype 2 and 3 HCV early viral kinetics, when administered over 2 weeks, alone or in combination with Peg-IFN alfa2a and REV, - to evaluate the single-dose and steady-state pharmacokinetics of telaprevir and VRT-127394, and the pharmacokinetic/pharmacodynamic relationship of telaprevir in subjects chronically infected with genotype 2 or 3 HCV; - to assess and characterize pheno- and genotypically resistant variants potentially arising after 2 weeks of telaprevir treatment with or without Peg-IFN alfa2a and RBV, in subjects chronically infected with genotype 2 or 3 HCV; - to evaluate the safety and tolerability of 2-week treatment with telaprevir with or without Peg-IFN alfa2a and RBV in subjects chronically infected with genotype 2 or 3 HCV. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female subjects, 18-65 years of age, inclusive. 2. Subjects chronically infected with either a) genotype 2 HCV with HCV RNA > 10,000 IU/mL, or b) genotype 3 HCV with HCV RNA >10,000 IU/mL. Chronic disease status must be confirmed by at least one of the following standard criteria: - history of a remote risk factor (e.g., intravenous drug abuse or blood transfusion), or abnormal alanine aminotransferase (ALT) levels for > 6 months prior to screening 'Note': elevated ALT is not an inclusion criterion if one of the other criteria for chronic HCV infection is met, or - diagnosis of hepatitis C > 6 months before the screening period. 3. Subject has never received treatment for HCV (including investigational products). 4. Screening laboratory values of the following variables must meet the acceptable values defined below: Absolute neutrophil count:>=1,500/mm3 Platelet count: >= 100,000/mm3 Hemoglobin: within normal range All other hematology and biochemistry results must show no clinically significant abnormalities in the opinion of the investigator. 5. Subjects judged to be in good health, in the opinion of the investigator, on the basis of medical history and physical examination (including vital signs and screening ECG), with any chronic medical conditions under stable medical control. 6. Subjects must agree to the use of two effective methods of contraception as outlined in Section 5.2.4, if heterosexually active, unless the male subject/partner has undergone a vasectomy or if the female subjectlpartner has had a bilateral oophorectomy, or a total hysterectomy, or if she is post-menopausal for at least two years. 7. Subject is willing to refrain from the concomitant use of any medications or substances noted in Section 5.3.11. 8. Subject has signed ICF voluntarily before the first trial-related activity. |
|
E.4 | Principal exclusion criteria |
1. Subject has a concomitant medical condition that in the opinion of the investigator could influence the results of the trial or that could represent an additional risk for the administration of the study medication to the subject. 2. Subject has medical contraindications to the administration of an interferon (Peg-IFN alfa2a in particular) or REW treatment, including but not limited to the following: - abnormal thyroid stimulating hormone (TSH) levels or poorly controlled thyroid function; - evidence of clinically significant cardiac dysfunction; - history of psychiatric disorders determined by the investigator to contraindicate the use of IFN-based therapy; - ANA titer>= 1:320; - history of hemoglobinopathies. 3. Subject has history or evidence of cirrhosis, end-stage or decompensated liver disease, or hepatocellular carcinoma as shown by screening laboratory results of any of the following: a. international normalized ratio (INR) >= 1.7; b. serum albumin < 3.5 g/dL; c. serum total bilirubin > 1.8 times the upper limit of normal (ULN), unless isolated and for subjects with Gilbert's Syndrome; d. history of ascitis, hepatic encephalopathy, bleeding esophageal varices; e. AFP > 50 ng/mL. 4. Subject has history or suspicion of alcohol, barbiturate, or amphetamine recreational or narcotic drug use, which in the investigator's opinion would compromise the subject's safety andlor compliance with study procedures. 5. Subject has HIV or HBV co-infection. 6. Women who are pregnant, planning to become pregnant, or breastfeeding, and partners of women who are pregnant or breastfeeding. 7. Subject has hypersensitivity to tartrazine. 8. Subject participated in any clinical trial for an investigational drug within 90 days before drug administration or participated in more than 2 drug studies in the last 12 months.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Plasma hepatitis C virus RNA level. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |